Trial Profile
Phase 2 Open-Label Safety and Immunogenicity Study of the Venezuelan Equine Encephalomyelitis (VEE) Vaccine, Live Attenuated, Dried, TC-83, NDBR 102, Lot 4, Run 3, as Primary Vaccination in Healthy Adult Subjects at Risk of Exposure to VEE Virus
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Venezuelan equine encephalitis virus vaccine (Primary)
- Indications Venezuelan equine encephalomyelitis
- Focus Adverse reactions
- 17 Dec 2019 Status changed from recruiting to active, no longer recruiting.
- 09 Oct 2018 Status changed from not yet recruiting to recruiting.
- 02 May 2018 Planned initiation date changed from 1 Mar 2018 to 1 Sep 2018.